B. Riley Equities Analysts Raise Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at B. Riley boosted their Q3 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of $0.14 for the quarter, up from their prior forecast of $0.04. B. Riley currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.44 EPS, FY2026 earnings at $1.08 EPS, FY2027 earnings at $1.45 EPS, FY2028 earnings at $1.66 EPS and FY2029 earnings at $1.82 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The business had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

Other equities analysts have also recently issued reports about the stock. Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Remove Ads

Eton Pharmaceuticals Trading Down 7.1 %

Shares of ETON stock traded down $1.05 on Friday, reaching $13.74. The company's stock had a trading volume of 170,017 shares, compared to its average volume of 160,487. The stock's fifty day simple moving average is $15.60 and its 200-day simple moving average is $11.77. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $18.41. The company has a market capitalization of $368.48 million, a price-to-earnings ratio of -62.45 and a beta of 1.37.

Institutional Trading of Eton Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at $86,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $54,000. Jefferies Financial Group Inc. purchased a new stake in Eton Pharmaceuticals in the 4th quarter worth about $133,000. Raymond James Financial Inc. bought a new stake in Eton Pharmaceuticals in the fourth quarter worth about $147,000. Finally, Bank of America Corp DE boosted its position in shares of Eton Pharmaceuticals by 5,422.4% during the fourth quarter. Bank of America Corp DE now owns 11,100 shares of the company's stock valued at $148,000 after buying an additional 10,899 shares during the period. 27.86% of the stock is currently owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.